On Thursday, Shares of Southwest Airlines Co (NYSE:LUV), gained 2.25% to $36.32.
Southwest Airlines’, declared a quarterly dividend of $.075 per share to Shareholders of record at the close of business on August 20, 2015 on all shares then issued and outstanding. The 156th successive dividend will be paid on September 10, 2015.
Southwest Airlines Co. operates passenger airlines that provide planned air transportation services in the United States and near-international markets. As of December 31, 2014, it operated 665 Boeing 737 aircraft; and had 12 Boeing 717 aircraft.
Shares of Chevron Corporation (NYSE:CVX), declined -0.18% to $93.08, during its last trading session.
Chevron Corporation, declared the “2015 Delo Pick-Up Your Truck Sweepstakes,” which offers participants a chance to win a 2015 Ford F-250 SRW 4×4 Crew Cab XLT Diesel Truck and other prizes. The Sweepstakes, which can be accessed via www.DeloPromos.com or the brand’s Facebook page (www.Facebook.com/ChevronDelo), runs from July 1, 2015 through August 31, 2015.
“The 2015 Delo Pick-Up Your Truck Sweepstakes offers our fans the chance to go further at work or at home in a new, reliable Ford F-250,” said Rommel Atienza, North America Commercial Brand Manager, Chevron Products Company. “Last year’s contest was such a success that we wanted to offer a Ford F-250 diesel pick-up again as the grand prize this year, which is the fifth year of the sweepstakes.”
Chevron Corporation, through its auxiliaries, engages in the petroleum, chemicals, and power and energy operations worldwide. The company operates in two segments, Upstream and Downstream.
Finally, Affymetrix, Inc. (NASDAQ:AFFX), ended its last trade with -1.55% loss, and closed at $10.78.
Affymetrix stated its operating results for the second quarter of 2015.
Results for the three months ended June 30, 2015:
- Stated revenue growth of 4.1% and 7.9% on a constant currency basis.
- Total revenue was $89.0 million, contrast to $85.4 million in second quarter of 2014.
- GAAP net income was $7.0 million, or $0.08 per diluted share, as contrast to a GAAP net loss of $0.9 million, or $0.01 per diluted share, in the second quarter of 2014, an enhance of $7.9 million or $0.09 per diluted share.
- Non-GAAP net income was $10.5 million, or $0.12 per diluted share, contrast to a non-GAAP net income of $5.2 million, or $0.07 per diluted share, for the second quarter of 2014. Please refer to “Itemized Reconciliation Between GAAP and Non-GAAP Net Income (Loss)” for a reconciliation of these GAAP and non-GAAP financial measures.
- The Company declared the acquisition of Eureka Genomics for $15 million in an all cash transaction.
- Net proceeds of $19.4 million were raised through an “at-the-market” offering.
- Total balance in cash and cash equivalents was $119.6 million and senior debt was $21.0 million as of June 30, 2015.
Affymetrix, Inc. provides life science products and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein, and cell level primarily in the United States, Europe, Latin America, and Asia. The company operates in two segments, Affymetrix Core and eBioscience.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
